Price
$649.81+22.45%1Y
1M-2.42%1Y+22.45%
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Above average8/10
Value64
Quality77
Momentum34
Growth66
P/E (TTM)14.7
Market Cap$63.95B
1Y Return+22.45%
5Y Return+20.05%
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q1 2026Total $6.17B (-4.98%)
●Product And Service Other grew +109.04% YoY●Eylea Net Product Sales -35.72% YoY
SegmentLatestQoQYoY
- Collaboration Revenue$1.90B-3.49%+24.07%
- Share Of Profit Losses$1.45B-0.32%+42.49%
- EYLEAHDAnd EYLEA$941.5M--9.71%
- Eylea Net Product Sales$473.1M-30.49%-35.72%
- EYLEAHD$468.4M-+52.67%
- LIBTAYONet Product Sales$286.1M+30.58%+48.62%
- Reimbursement Of Commercialization Related Expenses$184.1M+0.82%+15.64%
- Product And Service Other$171.2M-13.62%+109.04%
- Reimbursement For Manufacturing Of Commercial Supplies$154.3M-4.46%-6.48%
- Praluent Net Product Sales$66.6M-1.62%+17.25%
- Evkeeza$45.7M+6.78%+47.90%
- Other Products$31.3M+3812.50%-
- Lynozyfic$11.2M--
- Regenerons Obligation Of Research And Development Expenses Net Of Reimbursement Of Research And Development Expenses$1.0M--
- Amounts Recognized In Connection With Up Front Payments---
- Arcalyst Net Product Sales---
- ELYEAHDAnd EYLEA---
- ELYEAHD---
- Inmazeb---
- Net Profit In Connection With Commercialization---
- Next Generation Covid Antibodies---
- One Time Payment In Connection With Change In Japan Arrangement---
- Other Collaboration Agreements---
- Other---
- REGENCOV---
- Regenerons Share Of Commercial Expenses---
- Regenerons Share Of Research And Development Expenses---
- Reimbursement For Manufacturing Of Ex Commercial Supplies---
- Reimbursement Of Research And Development Expenses---
- Ronapreve---
- Sales Based Milestone Earned---
- Sales Based Milestones Earned---
- Sanofis Shareof Libtayo U.S.Gross Profits---
- Share Of Profit Losses In Connection With Commercialization---
- Reimbursement Of Research And Development Expenses Net Of Obligation For Share Of RDExpenses−$16.7M--